These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

155 related articles for article (PubMed ID: 16229965)

  • 1. Convert hepatitis C virus into a non-enveloped virus like hepatitis A, by targeting its envelope rather than the RNA.
    Helmy A
    Med Hypotheses; 2006; 66(4):847-50. PubMed ID: 16229965
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Twenty-four hour kinetics of hepatitis C virus and antiviral effect of alpha-interferon.
    Boulestin A; Kamar N; Sandres-Sauné K; Legrand-Abravanel F; Alric L; Vinel JP; Rostaing L; Izopet J
    J Med Virol; 2006 Mar; 78(3):365-71. PubMed ID: 16419107
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A Hepatitis C virus-host interaction involved in viral replication: toward the identification of antiviral targets.
    Suzuki T
    Jpn J Infect Dis; 2010 Sep; 63(5):307-11. PubMed ID: 20858994
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Hepatitis A virus infection suppresses hepatitis C virus replication and may lead to clearance of HCV.
    Deterding K; Tegtmeyer B; Cornberg M; Hadem J; Potthoff A; Böker KH; Tillmann HL; Manns MP; Wedemeyer H
    J Hepatol; 2006 Dec; 45(6):770-8. PubMed ID: 17034895
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Chemical genetics approach to hepatitis C virus replication: cyclophilin as a target for anti-hepatitis C virus strategy.
    Watashi K; Shimotohno K
    Rev Med Virol; 2007; 17(4):245-52. PubMed ID: 17299803
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The hepatitis C virus life cycle as a target for new antiviral therapies.
    Pawlotsky JM; Chevaliez S; McHutchison JG
    Gastroenterology; 2007 May; 132(5):1979-98. PubMed ID: 17484890
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Evaluation systems for anti-HCV drugs.
    Moriishi K; Matsuura Y
    Adv Drug Deliv Rev; 2007 Oct; 59(12):1213-21. PubMed ID: 17720275
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Oligonucleotide-based therapeutic options against hepatitis C virus infection.
    Trepanier JB; Tanner JE; Alfieri C
    Antivir Ther; 2006; 11(3):273-87. PubMed ID: 16759043
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Entry of hepatitis C virus and human immunodeficiency virus is selectively inhibited by carbohydrate-binding agents but not by polyanions.
    Bertaux C; Daelemans D; Meertens L; Cormier EG; Reinus JF; Peumans WJ; Van Damme EJ; Igarashi Y; Oki T; Schols D; Dragic T; Balzarini J
    Virology; 2007 Sep; 366(1):40-50. PubMed ID: 17498767
    [TBL] [Abstract][Full Text] [Related]  

  • 10. 3-Amino-2(5H)furanones as inhibitors of subgenomic hepatitis C virus RNA replication.
    Iannazzo D; Piperno A; Romeo G; Romeo R; Chiacchio U; Rescifina A; Balestrieri E; Macchi B; Mastino A; Cortese R
    Bioorg Med Chem; 2008 Nov; 16(21):9610-5. PubMed ID: 18835180
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Novel hepatitis C drugs in current trials.
    Kronenberger B; Welsch C; Forestier N; Zeuzem S
    Clin Liver Dis; 2008 Aug; 12(3):529-55, viii. PubMed ID: 18625427
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Hepatitis C virus genetic variability in patients undergoing antiviral therapy.
    Cristina J; del Pilar Moreno M; Moratorio G
    Virus Res; 2007 Aug; 127(2):185-94. PubMed ID: 17449128
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Molecular mechanisms of the hepatitis C virus, potential therapeutic targets].
    Rivas-Estilla AM; Panduro A
    Rev Invest Clin; 2003; 55(1):51-64. PubMed ID: 12708164
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Novel insights into hepatitis C virus replication and persistence.
    Bartenschlager R; Frese M; Pietschmann T
    Adv Virus Res; 2004; 63():71-180. PubMed ID: 15530561
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cellular models for the screening and development of anti-hepatitis C virus agents.
    Gondeau C; Pichard-Garcia L; Maurel P
    Pharmacol Ther; 2009 Oct; 124(1):1-22. PubMed ID: 19555718
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Hepatitis C virus entry: an intriguing challenge for drug discovery.
    Meanwell NA
    Curr Opin Investig Drugs; 2006 Aug; 7(8):727-32. PubMed ID: 16955684
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Antiviral effect of ribonuclease conjugated oligodeoxynucleotides targeting the IRES RNA of the hepatitis C virus.
    Gamble C; Trotard M; Le Seyec J; Abreu-Guerniou V; Gernigon N; Berrée F; Carboni B; Felden B; Gillet R
    Bioorg Med Chem Lett; 2009 Jul; 19(13):3581-5. PubMed ID: 19450979
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Structural biology of hepatitis C virus.
    Penin F; Dubuisson J; Rey FA; Moradpour D; Pawlotsky JM
    Hepatology; 2004 Jan; 39(1):5-19. PubMed ID: 14752815
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Virology of hepatitis B and C viruses and antiviral targets.
    Pawlotsky JM
    J Hepatol; 2006; 44(1 Suppl):S10-3. PubMed ID: 16338022
    [TBL] [Abstract][Full Text] [Related]  

  • 20. New efficient replication system with hepatitis C virus genome derived from a patient with acute hepatitis C.
    Mori K; Abe K; Dansako H; Ariumi Y; Ikeda M; Kato N
    Biochem Biophys Res Commun; 2008 Jun; 371(1):104-9. PubMed ID: 18406345
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.